From 1984 through 1986, 205 patients with non-small cell lung cancer were entered into a group-wide trial of the Swiss Group for Clinical Cancer Research (SAKK). This trial evaluated the combination of mitomycin (8 mg/m2 intravenously [IV] on day 1), vindesine (3 mg/m2 IV on days 1 and 8), and cisplatin (60 mg/m2 IV on day 1) with forced diuresis, repeated every 4 weeks (MiViP regimen). One hundred eighty-three patients were evaluable. Six complete and 69 partial responses were documented for an overall response rate of 41% (95% confidence interval, 34% to 50%). In the multivariate analysis the strongest predictors for response were the participating institution and the number of initially involved organ sites. The estimated median time to ...
Background. The MIP regimen (mitomycin, ifosfamide, cisplatin) demonstrated its effectiveness as fir...
We aimed to evaluate, in a phase II study, the efficacy of the mitomycin-vinorelbine combination in ...
A regimen consisting of 5-fluorouracil, vincristine, bleomycin, cyclophosphamide and mitomycin C (FO...
From 1984 through 1986, 205 patients with non-small cell lung cancer were entered into a group-wide ...
Six hundred eighty assessable patients with measur-able stage III M1 non-small-cell lung cancer (NSC...
In order to compare the efficacy and toxicity of cis-platinum and mitomycin C in advanced non-small ...
During the last decade, the Eastern Cooperative Oncol-ogy Group (ECOG) has studied a series of combi...
MVP chemotherapy (mitomycin C, vindesine or vinblastine, cisplatin) is one of the most commonly used...
Fifty-two patients with extensive small lung cancer entered a study of cyclic alternating combinatio...
Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly as...
Between February 1986 and September 1987, we conducted a phase Ⅱ clinical trial of a three-drug comb...
Standard chemotherapeutic regimens, such as cisplatin and etoposide, may improve quality of life and...
Aim of this study was to determine the activity and toxicity of a sequential chemotherapy regimen in...
BACKGROUND: To determine the activity and safety of a sequential regimen of cisplatin and vinorelbin...
Forty-five stage IIIB-IV non-small cell lung cancer (NSCLC) patients entered a phase II study design...
Background. The MIP regimen (mitomycin, ifosfamide, cisplatin) demonstrated its effectiveness as fir...
We aimed to evaluate, in a phase II study, the efficacy of the mitomycin-vinorelbine combination in ...
A regimen consisting of 5-fluorouracil, vincristine, bleomycin, cyclophosphamide and mitomycin C (FO...
From 1984 through 1986, 205 patients with non-small cell lung cancer were entered into a group-wide ...
Six hundred eighty assessable patients with measur-able stage III M1 non-small-cell lung cancer (NSC...
In order to compare the efficacy and toxicity of cis-platinum and mitomycin C in advanced non-small ...
During the last decade, the Eastern Cooperative Oncol-ogy Group (ECOG) has studied a series of combi...
MVP chemotherapy (mitomycin C, vindesine or vinblastine, cisplatin) is one of the most commonly used...
Fifty-two patients with extensive small lung cancer entered a study of cyclic alternating combinatio...
Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly as...
Between February 1986 and September 1987, we conducted a phase Ⅱ clinical trial of a three-drug comb...
Standard chemotherapeutic regimens, such as cisplatin and etoposide, may improve quality of life and...
Aim of this study was to determine the activity and toxicity of a sequential chemotherapy regimen in...
BACKGROUND: To determine the activity and safety of a sequential regimen of cisplatin and vinorelbin...
Forty-five stage IIIB-IV non-small cell lung cancer (NSCLC) patients entered a phase II study design...
Background. The MIP regimen (mitomycin, ifosfamide, cisplatin) demonstrated its effectiveness as fir...
We aimed to evaluate, in a phase II study, the efficacy of the mitomycin-vinorelbine combination in ...
A regimen consisting of 5-fluorouracil, vincristine, bleomycin, cyclophosphamide and mitomycin C (FO...